Eli Lilly's Acquisition of Kelonia Therapeutics: A Major Step Forward in CAR-T Cell Therapies

Eli Lilly's Major Acquisition of Kelonia Therapeutics

Eli Lilly and Company has made a significant move in the biotechnology field by announcing its acquisition of Kelonia Therapeutics, a clinical-stage company that is pushing the boundaries of in vivo CAR-T cell therapies. This acquisition holds promise not only for Lilly’s growth but also for patients suffering from multiple myeloma, a type of blood cancer.

On April 20, 2026, both firms confirmed the agreement that will allow Lilly to enhance its existing capabilities in genetic medicine through Kelonia's innovative in vivo gene placement system (iGPS®). This proprietary technology utilizes lentiviral-based particles that can efficiently enter T-cells directly inside the patient's body, allowing for the generation of CAR-T therapies that can potentially treat underlying diseases more effectively than existing methods.

Kelonia's flagship therapy, KLN-1010, currently undergoing Phase 1 clinical trials, is particularly noteworthy. It represents a novel one-time intravenous gene therapy designed to generate anti-B-cell maturation antigen (BCMA) CAR-T cells, specifically targeting multiple myeloma cells. Recent presentations of its initial clinical results at the 2025 American Society of Hematology Annual Meeting showcased promising tolerability, reinforcing the therapy's potential as a transformative option for patients.

In previous years, CAR-T therapies have proven effective for various cancers, significantly improving patient outcomes. However, the complex and costly nature of manufacturing these therapies has hindered access for many eligible patients. The in vivo platform developed by Kelonia is seen as a game-changer that could facilitate faster, more durable responses to treatment in a simpler, off-the-shelf format.

Jacob Van Naarden, Lilly's Executive Vice President and President of Lilly Oncology, expressed optimism about this acquisition, saying, “The early clinical data for KLN-1010 are highly encouraging... We look forward to working with the Kelonia team to rapidly advance KLN-1010 and fully realize the potential of their platform in treating other conditions.”

Kelonia Therapeutics stands out in the realm of genetic medicine for its dedication to advancing in vivo therapies, aiming to make CAR-T treatments more accessible. CEO Kevin Friedman highlighted their achievements in achieving deep remissions in multiple myeloma cases with less complexity and cost than traditional ex vivo therapies. The integration of Lilly’s resources is poised to enhance Kelonia's reach, aiming to revolutionize treatment options across a broader spectrum of cancers.

Under the terms of the agreement, Lilly is set to acquire Kelonia for a deal valued at up to $7 billion, which includes an initial payment of $3.25 billion and additional payments as certain clinical and commercial milestones are realized. As the transaction awaits customary regulatory approvals, it is anticipated to close in the latter half of 2026.

This acquisition marks a critical step for Lilly, enabling it to further its mission to produce pioneering and transformative therapies for significant health challenges. Both companies are poised to work collaboratively, leveraging Lilly’s established infrastructure and Kelonia’s ground-breaking technology to expedite the advancement of innovative treatments.

For Lilly, legal counsel is provided by Kirkland & Ellis LLP, while Jefferies LLC has taken on the role as financial advisor for Kelonia, supported by Goodwin Procter LLP in legal matters. The synergy generated from this merger aims not only to propel research and development efforts but ultimately to enhance patient care and improve outcomes for those fighting cancer.

The ongoing journey of enhancing access to effective treatment options for cancer patients is vital, and this acquisition exemplifies the commitment of both Lilly and Kelonia to break through the current limitations in personalized medicine. As they continue to progress, developments will be closely monitored by both analysts and patients awaiting the next generation of CAR-T therapies.